Phentermine HCl

A to Z Drug Facts

Phentermine HCl

 Actions
 Indications
 Contraindications
 Route/Dosage
 Interactions
 Lab Test Interferences
 Adverse Reactions
 Precautions
Patient Care Considerations
 Administration/Storage
 Assessment/Interventions
 Patient/Family Education


(FEN-ter-meen)
Phentermine HCl
Tablets: 8 mg (equiv. to 6.4 mg base), 30 mg (equiv. to 24 mg base), 37.5 mg (equiv. to 30 mg base)
Capsules: 15 mg (equiv. to 12 mg base), 18.75 mg (equiv. to 15 mg base), 37.5 mg (equiv. to 30 mg base)
Ionamin
Capsules: 15 mg phentermine resin, 15 mg (as resin complex), 30 mg (as resin complex)
Adipex-P
Tablets: 37.5 mg (equiv. to 30 mg base)
Capsules: 37.5 mg (equiv. to 30 mg base)
Obe-Nix 30
Capsules: 37.5 mg (equiv. to 30 mg base)
Phentermine Resin
Capsules: 15 mg (as resin complex), 30 mg (as resin complex)
Class: CNS stimulant/Anorexiant

 Actions May stimulate satiety center in brain, causing appetite suppression.

 Indications Short-term (few weeks) adjunct to diet plan to reduce weight.

 Contraindications Hypersensitivity to sympathomimetic amines; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse; during or within 14 days following the administration of an MAOI.

 Route/Dosage

8 mg Dose

ADULTS and CHILDREN (³ 12 yr): PO 8 mg up to 3 times daily ½ hour before meals.

15 to 37.5 mg Dose

ADULTS and CHILDREN (> 16 yr): PO 15 to 37.5 mg as a single dose before breakfast or 2 hr after breakfast.

 Interactions

Guanethidine: May decrease hypotensive effect of guanethidine. MAOIs (eg, phenelzine); furazolidone: May cause hypertensive crisis and intracranial hemorrhage. Selective serotonin reuptake inhibitors (eg, fluoxetine): Sympathomimetic effects of phentermine and risk of “serotonin syndrome” may be increased.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Regurgitant cardiac valvular disease; palpitation; tachycardia; hypertension. CNS: Overstimulation; restlessness; dizziness; insomnia; euphoria; dysphoria; tremor; headache; psychotic episodes. DERMATOLOGIC: Allergic urticaria. GI: Dry mouth; unpleasant taste; diarrhea; constipation. GU: Impotence; changes in libido. RESPIRATORY: Primary pulmonary hypertension.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: 8 mg dose-Safety and efficacy not established in children < 12 yr. 16 mg dose-Safety and efficacy not established in children £ 16 yr. Special risk patients: Use with caution in patients with glaucoma, hypertension, and diabetes mellitus. Drug dependence: Psychological and physical dependence may occur with continued use; this class of drugs has been extensively abused. Tolerance: Tolerance to the anorectic effect usually develops within a few weeks. Primary pulmonary hypertension: Has been reported with concurrent use of phentermine and fenfluramine or dexfenfluramine. Valvular heart disease: Serious regurgitant cardiac valvular disease has been reported with concurrent use of phentermine and fenfluramine or dexfenfluramine.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
 Restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, fatigue, depression, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps, convulsions, coma, death

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts

-->